GT Medical Technologies key facts
as of Oct 2026- Developer of a medical therapeutic device designed to overcome the limitations of current treatments by placing it after the tumor removal.
- GT Medical Technologies is valued at approximately $215.3M as of Oct 2026, set at its later-stage round, Jun 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $161.5M across 6 recorded rounds; the latest was Later Stage VC ($53.3M) in Dec 2024.
- Notable investors include MedTech Innovator, Gilde Healthcare, Arizona Commerce Authority, FemHealth Ventures, Flinn Foundation — 18 tracked in total.
- GT Medical Technologies has filed 8 Form Ds with the SEC since 2017, most recently Jun 2025 ($53.3M sold to 37 investors).
- Status: Privately Held (backing).
Valued at $215.3M at its later-stage round, Jun 2025. Nothing has traded since.
- ·The complete investor list: 18 names
- ·Watch GT Medical Technologies: the Monday email on marks, rounds and moves
GT Medical Technologies funding rounds
6 roundsWho backs GT Medical Technologies
18+GT Medical Technologies valuation
GT Medical Technologies was valued at $215 million at its later-stage round in Jun 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has GT Medical Technologies raised?
GT Medical Technologies has raised $161 million across 6 recorded rounds since 2017. The largest was a $5.6 million early-stage round in Nov 2018; the most recent was a $53.3 million later-stage round in Dec 2024.
GT Medical Technologies has filed 8 Form Ds with the SEC since 2017, most recently in Jun 2025 ($53.3 million sold to 37 investors).
GT Medical Technologies investors
18 investors are on record for GT Medical Technologies, including MedTech Innovator, Gilde Healthcare, Arizona Commerce Authority and FemHealth Ventures. The later-stage round in Dec 2024 drew 37 investors.
About GT Medical Technologies
Developer of a medical therapeutic device designed to overcome the limitations of current treatments by placing it after the tumor removal. The company's device features a bioresorbable, conformable, collagen tile and a uniform radiation source that utilizes advanced brachytherapy techniques, minimizing radiation exposure to healthy tissue, reducing side effects, and decreasing treatment burden, enabling medical practitioners to prevent disease progression and improving the quality of life for their patients.
- Sector
- Healthcare
- HQ
- Tempe, AZ, United States
- Founded
- 2017
- Employees
- 100
- Website
- gammatile.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.